22nd week of 2017 patent applcation highlights part 16 |
Patent application number | Title | Published |
20170152189 | PLASMA-RESISTANT MEMBER - There is provided a plasma-resistant member, including: a base material; and a layer structural component formed by aerosol deposition at a surface of the base material, the layer structural component being plasma-resistant and including an yttria polycrystalline body, the yttria polycrystalline body included in the layer structural component having a crystal structure in which cubic and monoclinic coexist, a proportion of monoclinic to cubic inside the yttria polycrystalline body included in the layer structural component being not less than 0% and not more than 60%, a crystallite size of the yttria polycrystalline body included in the layer structural component being not less than 8 nm and not more than 50 nm. | 2017-06-01 |
20170152190 | LIGHTWEIGHT SOUND-ABSORBING AND FIRE-RESISTANT INSULATION PANEL USING EXPANDED GRAPHITE AND SWELLING CLAY AND METHOD FOR MANUFACTURING THE SAME - The present invention relates to a lightweight sound-absorbing and fire-resistant insulation panel including: a binder; expanded graphite; and swelling clays, and the swelling clays are formed of honeycomb-shaped layered clays containing water molecules in interlayers and have particle sizes in the range of 50 to 200 μm. Further, the expanded graphite is present in an amount of from 10 to 100 parts by weight per 100 parts by weight of the swelling clays. According to the present invention, the insulation panel is made of the expanded graphite and the honeycomb-shaped swelling clays, thus providing excellent lightweightness, sound absorption, insulation, fire resistance and flame retardancy, and further, the insulation panel is manufactured without having any sintering, thus providing simple manufacturing processes and lowering production costs. | 2017-06-01 |
20170152191 | FORMATION OF BORON CARBIDE-BORON NITRIDE CARBON COMPOSITIONS - A composition having nanoparticles of a boron carbide and a carbonaceous matrix. The composition is not in the form of a powder. A composition comprising boron and an organic component. The organic component is an organic compound having a char yield of at least 60% by weight or a thermoset made from the organic compound. A method of combining boron and an organic compound having a char yield of at least 60% by weight, and heating to form boron carbide or boron nitride nanoparticles. | 2017-06-01 |
20170152192 | CERAMIC SUBSTRATE AND ITS MANUFACTURING METHOD, POWER MODULE - Provided is a ceramic substrate. The ceramic substrate includes a core layer, made of zirconia toughened alumina; and surface layers, symmetrically located on an upper and a lower surfaces of the core layer, made of Al | 2017-06-01 |
20170152193 | Ceramic Grains and Method for Their Production - The disclosure relates to sintered ceramic grains comprising 3-55 wt. % alumina, 40-95 wt. % zirconia and 1-30 wt. % of one or more other inorganic components. | 2017-06-01 |
20170152194 | METHOD FOR ENHANCING SOIL GROWTH USING BIO-CHAR - A method is described for rendering char from a biomass fractionator apparatus (BMF char) suitable for addition to soil in high concentrations, the method relying on multiple processes comprising removing detrimental hydrocarbons from BMF char, removing adsorbed gases from BMF char, introducing microorganisms to the BMF char, and adjusting soil pH. | 2017-06-01 |
20170152195 | Process for the Preparation of Humic Extracts from Fossil Sources - The present invention relates to a process for the preparation of fertilizing compositions and to the compositions obtained. | 2017-06-01 |
20170152196 | IGNITION COMPOSITIONS, AND PREPARATIONS AND USES THEREOF - An ignition composition comprising a low electron affinity material, an oxidizer and a binder. The ignition composition may be made by A1) preparing a coagulation composition by a shock-gel process using the ingredients of the ignition composition disclosed herein, which comprises: A1-a) dissolving the binder in a low-boiling-point polar solvent to provide a binder solution; A1-b) mixing the low electron affinity material and the oxidizer with the binder solution; and A1-c) adding a low-boiling-point non-polar solvent to the mixture provided by step 1-b) to precipitate the binder and form the coagulation composition; and A2) converting the coagulation composition into granular composition using a suitable method. | 2017-06-01 |
20170152197 | METHOD FOR PREPARING P-XYLENE AND CO-PRODUCING PROPYLENE WITH HIGH SELECTIVITY - A method for preparing p-xylene and co-producing propylene with a high selectivity, comprising: | 2017-06-01 |
20170152198 | HEAT INTEGRATION IN DISPROPORTIONATION OR TRANSALKYLATION PROCESSES - Toluene disproportionation and C9/C10 transalkylation are a significant source of xylenes in a modern aromatics complex. Methods and apparatuses for improving the energy efficiency of these disproportionation and transalkylation processes are provided. | 2017-06-01 |
20170152199 | METHOD OF DEPOLYMERIZING LIGNIN - A method of depolymerizing lignin and to the use of this method in the production of fuels, electronic components, plastic polymers, rubber, medicines, vitamins, cosmetic products, perfumes, foodstuffs, synthetic threads and fibres, synthetic leathers, adhesives, pesticides and fertilizers is provided. It also relates to a method of producing fuels, electronic components, plastic polymers, rubber, medicines, vitamins, cosmetic products, perfumes, foodstuffs, synthetic threads and fibres, synthetic leathers, adhesives, pesticides and fertilizers, including a step of depolymerizing lignin using the method according to the invention. | 2017-06-01 |
20170152200 | Zeolite Catalyst for Lignin to Phenol Conversion - A method for converting lignin to a phenol product, the method comprising contacting a zeolite catalyst with a lignin under reaction conditions sufficient to produce the phenol product at a yield of equal to or greater than about 50%. A method for converting lignin to a mixed phenol product, the method comprising contacting a large-pore zeolite catalyst with a Kraft lignin under reaction conditions comprising a reaction temperature of from about 550° C. to about 850° C. to produce the mixed phenol product at a yield of equal to or greater than about 50%. | 2017-06-01 |
20170152201 | Process and System for Making Cyclohexanone - Disclosed are processes and systems for making cyclohexanone from a mixture comprising phenol, cyclohexanone, and cyclohexylbenzene comprising a step of or a device for subjecting at least a portion of the mixture to hydrogenation and a step of or a device for distilling a phenol/cyclohexanone/cyclohexylbenzene mixture to obtain an effluent rich in cyclohexanone. | 2017-06-01 |
20170152202 | PROCESS FOR THE PREPARATION OF A PHENYLINDAN PHOTOINITIATOR - The present invention refers to a process for producing 5-[4-(2-hydroxy-2-methyl)-1-oxo-prop-1-yl]-3-[4-(2-hydroxy-2-methyl)-1-oxo-prop-1-yl-phenyl]-2,3-dihydro-1,1,3-trimethyl-1H-indene (dimer isomer 5) that comprises the acylation of cumene in the 4-position with an isobutyryl halide, followed by benzylic halogenation and dimerization (cyclization) of the resulting product. | 2017-06-01 |
20170152203 | POLYETHYLENE TEREPHTHALATE DEPOLYMERIZATION - The present invention relates to the depolymerization of polymers and the recovery of the starting materials used for the production of the polymer. The present invention also relates to the depolymerization of polyethylene terephthalate (PET) and the recovery of terephthalic acid and ethylene glycol. | 2017-06-01 |
20170152204 | LACTIC ACID MANUFACTURING METHOD - A method of producing lactic acid includes subjecting a lactic acid-containing solution to distillation to collect lactic acid from the vapor side (Step A); subjecting the lactic acid obtained in Step A to crystallization (Step B); subjecting the lactic acid slurry obtained in Step B to solid-liquid separation into lactic acid crystals and a mother liquor (Step C); and circulating the mother liquor obtained in Step C to Step B (Step D). | 2017-06-01 |
20170152205 | HIGH-AND LOW-VISCOSITY ESTOLIDE BASE OILS AND LUBRICANTS - Provided herein are compounds of the formula: | 2017-06-01 |
20170152206 | IRE-1alpha INHIBITORS - Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies. | 2017-06-01 |
20170152207 | COMPOSITIONS AND METHODS FOR HYDROCARBON FUNCTIONALIZATION - Embodiments of the present disclosure provide for methods of hydrocarbon functionalization, methods and systems for converting a hydrocarbon into a compound including at least one group ((e.g., hydroxyl group) (e.g., methane to methanol)), functionalized hydrocarbons, and the like. | 2017-06-01 |
20170152208 | METHOD FOR PROVIDING AN ACTIVE RUTHENIUM CATALYST SOLUTION FOR THE TRANSVINYLATION OF CARBOXYLIC ACIDS - The invention relates to a method for providing a ruthenium catalyst solution which is active during the transvinylation of a surfactant vinyl ester with a surfactant carboxylic acid, comprising an Ru metal concentration of more than 0.5 wt. % based on the total weight of the ruthenium catalyst solution. The invention is characterized in that a) at least one ruthenium (III) halogenide with at least one inorganic or organic base, at least one surfactant vinyl ester, and at least one surfactant carboxylic acid is reacted at a temperature of 70° C. to 170° C.; b) the molar ratio of surfactant vinyl ester to surfactant carboxylic acid is 1:1.8 to 1.8:1; and c) the ruthenium (III) halogenide is used in a quantity of >0.5 wt. % of Ru metal based on the total weight of the surfactant vinyl ester and surfactant carboxylic acid. | 2017-06-01 |
20170152209 | ULTRA HIGH-VISCOSITY ESTOLIDE BASE OILS AND METHOD OF MAKING THE SAME - Provided herein are methods of making estolide base oils, including those having a high kinematic viscosity. In certain embodiments, an ultra high-viscosity estolide base oil is prepared from hydroxy fatty acids derived from the hydrolysis of a first estolide base oil. | 2017-06-01 |
20170152210 | METHODS FOR PRODUCING CHEMICAL PRODUCTS WITH OPERATION INTERRUPTIONS - This invention relates to methods for producing chemical products, wherein the one or more feed materials are reacted to form a chemical product or a chemical composition. The invention further relates to plants for performing such methods, said plants being designed in such a way that, during an interruption of the methods, no input of at least one feed material into the reaction occurs and the plant parts not affected by a revision measure, maintenance measure, repair measure, or cleaning measure are operated in so-called re-circulation mode. It is thereby achieved, among other things, that only the affected plant part needs to be shut down for the time of the measure, which can be advantageous with regard to the productivity and economy of the method and the quality of the produced products. Finally, the invention relates to methods for operating plants in the event that individual plant parts are taken out of service. | 2017-06-01 |
20170152211 | INTEGRATED PROCESS FOR NITRILE MANUFACTURE WITH ENHANCED LIQUID-LIQUID EXTRACTION - Phosphorus-containing ligands are recovered from mixtures comprising 3-pentenenitrile (3PN) and adiponitrile (ADN), using liquid-liquid extraction. ADN is produced by hydrocyanation of 3PN. The ADN is hydrogenated to produce a hexa-methyiene diamine (HMD) and at least one byproduct including bis-hexamethylene triamine (BHMT) or 1,2-diaminocyclohexane. At least a portion of the HMD product or byproduct is used to enhance the liquid-liquid extraction to recover phosphorus-containing ligand. | 2017-06-01 |
20170152212 | METHOD FOR PREPARING N,N'-BIS(3-AMINOPROPYL)-1,2-ETHYLENEDIAMINE - A method for preparing N,N′-bis(3-aminopropyl)-1,2-ethylenediamine uses a glycol ether based solution, such as a solution containing dipropylene glycol dimethyl ether (PM) to replace the traditionally used monol-based solvents, and performs hydrogenation in the presence of a Co—Mn—Al catalyst. The method improves the yield of N,N′-bis(3-aminopropyl)-1,2-ethylenediamine to 98.85-99.49% and effectively suppresses generation of by-products. | 2017-06-01 |
20170152213 | AMINE-CONTAINING LIPIDOIDS AND USES THEREOF - Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino moiety of the lipidoids, they are well-suited for the delivery of polynucleotides, in addition to other agents. Nanoparticles containing the inventive lipidoids and polynucleotides have been prepared and have been shown to be effective in delivering siRNA. | 2017-06-01 |
20170152214 | INSECTICIDAL COMPOUNDS - The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests | 2017-06-01 |
20170152215 | METHOD FOR PREPARING N,N'-BIS(2-CYANOETHYL)-1,2-ETHYLENEDIAMINE - A method for preparing N,N′-bis(2-cyanoethyl-1,2-ethylenediamine involves using glycol ether as a catalyst for synthesis reaction in which ethylenediamine and acrylonitrile at a molar ratio of 1:1.9-2.1 are reactant that react at 20-70°C to prepare N,N′-bis(2-cyanoethyl)-1,2-ethylenediamine; the method improves the yield to 98.15-98.98%; and the used glycol ether may be filtered and recycled, thereby saving costs and reducing environmental pollution. | 2017-06-01 |
20170152216 | METHOD FOR PREPARING N,N'-BIS(2-CYANOETHYL)-1,2-ETHYLENEDIAMINE BY USING CATION EXCHANGE RESIN AS CATALYST - A method for preparing N,N′-bis(2-cyanoethyl)-1,2-ethylenediamine involves using strongly acidic cation exchange resin as a catalyst for synthesis, and is advantageous for not only eliminating the need of distillation for purification and thereby reducing reaction time, but also improving the yield of N,N′-bis(2-cyanoethyl)-1,2-ethylenediamine to 97.70-98.08%; and the method benefits simplified process and reduced costs and helps to save water significantly, thereby minimizing environmental pollution. | 2017-06-01 |
20170152217 | FINE PURIFICATION OF ISOPHORONENITRILE BY MELT CRYSTALLIZATION - The present invention relates to the fine purification of isophoronenitrile (IPN) by melt crystallization. | 2017-06-01 |
20170152218 | PROCESS FOR PRODUCTION OF AMMONIA AND DERIVATIVES, IN PARTICULAR UREA - A process for producing ammonia and a derivative of ammonia from a natural gas feed comprising conversion of natural gas into a make-up synthesis gas; synthesis of ammonia; use of said ammonia to produce said derivative of ammonia, wherein a portion of the natural gas feed is used to fuel a gas turbine; power produced by said gas turbine is transferred to at least one power user of the process, such as a compressor; heat is recovered from exhaust gas of said gas turbine, and at least part of said heat is recovered as low-grade heat available at a temperature not greater than 200° C., to provide process heating to at least one thermal user of the process, such as CO2 removal unit or absorption chiller; a corresponding plant and method of modernization are also disclosed. | 2017-06-01 |
20170152219 | METHOD FOR THE MANUFACTURE OF UREA - A method for producing urea. A methane-containing feed gas stream is reacted with oxygen by partial oxidation to form a synthesis gas stream containing hydrogen and carbon monoxide. The carbon monoxide is reacted with water in a water gas-shift reaction to form carbon dioxide and hydrogen. The synthesis gas stream is separated into a first synthesis gas substream a second synthesis gas substream. The first synthesis gas substream is subjected to pressure-swing adsorption to separate hydrogen and the second synthesis gas substream is subjected to temperature-swing adsorption to separate carbon dioxide. The separated is reacted with nitrogen to form ammonia and the ammonia is reacted with the carbon dioxide to form urea. | 2017-06-01 |
20170152220 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED AN ACCUMULATION OF MISFOLDED PROTEINS - The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof Formula (I), and its uses to treat a disorder associated with protein misfolding stress and in particular with an accumulation of misfolded proteins. | 2017-06-01 |
20170152221 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein “R | 2017-06-01 |
20170152222 | COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE - The invention provides a method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual a composition comprising a compound set forth in FORMULA (I): | 2017-06-01 |
20170152223 | LIPID PARTICLES WITH CATIONIC LIPIDS FOR RNA DELIVERY - What is described is a lipid particle comprising the compound of formula I | 2017-06-01 |
20170152224 | NOVEL PROSTAMIDES FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES - Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma. | 2017-06-01 |
20170152225 | METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE - The present invention relates to methods of synthesising aziridines including isotopically labelled aziridines, said methods comprising contacting an imine or one or more precursors thereof with a diazo compound in the presence of a phosphoramide or a phosphoramide-derived catalyst. The present invention also relates to aziridines, modified aziridines and aziridine-derived compounds preparable by the aforementioned methods, and to phosphoramide or phosphoramide-derived catalysts suitable for use in such methods. | 2017-06-01 |
20170152226 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS - The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a disease or disorder, such as a proliferative disease (preferably cancer), using compounds of the invention. | 2017-06-01 |
20170152227 | Novel Polymorphic Form of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-2,2,3,3-tetrafluoropropoxy)benzylam- ine hydrochoride for the treatment of Alzheimer's - The present invention relates to a novel polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride. | 2017-06-01 |
20170152228 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS - Disclosed are methods for preparing and screening for an inhibitor of the activity of a biological molecule having a catalytic or non-catalytic cysteine residue. The methods including preparing a library of candidate inhibitor molecules by conjugating an electrophile to a plurality of drug molecules where the library of candidate inhibitor molecules thus formed react with cysteine residues. The library of candidate inhibitor molecules then may be reacted with the biological molecule to identify those inhibitor molecule that react with the catalytic or non-catalytic cysteine residue of the biological molecule in order to identify an inhibitor of the biological molecule. | 2017-06-01 |
20170152229 | TETRAHYDROISOQUINOLINONE DERIVATIVES AND THEIR USE IN THE INHIBITION OF THE HSP70 PROTEIN - The present invention relates to tetrahydroisoquinolinone derivatives, a pharmaceutical composition comprising the same and the use of these derivatives in the inhibition of the Hsp70 protein. The compounds are useful in the treatment or inhibition of cancer, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease and psoriasis. | 2017-06-01 |
20170152230 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc. | 2017-06-01 |
20170152231 | SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR - A method of preparing a 2,6 disubstituted anilines includes, reacting a 2-amino isophthalic acid diester with sufficient Grignard reagent R | 2017-06-01 |
20170152232 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND - As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer. | 2017-06-01 |
20170152233 | AMINO QUINAZOLINES AS KINASE INHIBITORS - Disclosed are compounds having the formula: | 2017-06-01 |
20170152234 | COMPOSITIONS AND METHODS FOR QUADRICYCLANE MODIFICATION OF BIOMOLECULES - The present disclosure features a strain-promoted [2+2+2] reaction that can be carried out under physiological conditions. In general, the reaction involves reacting a pi-electrophile with a low lying LUMO with a quadricyclane on a biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo and in vitro. The reaction is compatible with modification of living cells. In certain embodiments, the pi-electrophile can comprise a molecule of interest that is desired for delivery to a quadricyclane-containing biomolecule via [2+2+2] reaction. | 2017-06-01 |
20170152235 | NOVEL FORM OF TRIBENURON-METHYL, A PROCESS FOR ITS PREPARATION AND USE OF THE SAME - A crystalline form of tribenuron-methyl of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. The invention also describes the use of various solvents towards the crystalline form preparation conditions. | 2017-06-01 |
20170152236 | ENERGY EFFICIENT MANUFACTURING PROCESS FOR PREPARING N,O-TRIGLYCIDYL AMINOPHENOLS - The invention relates to an improved process for making monomeric triglycidyl compounds, wherein the triglycidyl compounds include N, O-triglycidyl compounds containing at least one primary aromatic amine and one phenolic functional group attached to the same or a different aromatic ring. The methods of the present invention result in the production of N, O-triglycidyl compounds, such as those of formula I and II. The improved process is energy efficient, environment friendly, and results in increased yields of product. The methods of the present invention can be performed in the absence of protic organic co-solvents during the reaction of an epihalohydrin with an aminophenol, such as compounds of formula II and IV, which provides an intermediate halohydrin compound. The methods of the present invention may also be performed in the absence of a phase transfer catalyst. | 2017-06-01 |
20170152237 | PROCESS FOR THE PRODUCTION OF FURAN AND ITS DERIVATIVES - The present invention provides a process for the treatment of a liquid first furan stream comprising furan and carbon monoxide, said process comprising the steps of: i) contacting said first furan stream with a CO-lean first gaseous stream; and ii) stripping at least a portion of the carbon monoxide in the first furan stream into the first gaseous stream to produce a second furan stream comprising less carbon monoxide than the first furan stream and a CO-enriched second gaseous stream. | 2017-06-01 |
20170152238 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS - Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same. | 2017-06-01 |
20170152239 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS - This invention relates to compounds of general formula | 2017-06-01 |
20170152240 | COT MODULATORS AND METHODS OF USE THEREOF - The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof. | 2017-06-01 |
20170152241 | BICYCLIC DERIVATIVE CONTAINING PYRIMIDINE RING, AND PREPARATION METHOD THEREFOR - The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT | 2017-06-01 |
20170152242 | PYRAZINE DERIVATIVES - Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like. | 2017-06-01 |
20170152243 | ALLISARTAN ISOPROXIL POLYMORPH, ITS PREPARATION METHOD AND PHARMACEUTICAL - Disclosed are polymorph of allisartan isoproxil and a pharmaceutical composition thereof. The polymorph is non-electrostatic, highly flowable and highly stable, and can be used for treating hypertension and complications thereof. | 2017-06-01 |
20170152244 | bis-Pyridazine Compounds and Their Use in Treating Cancer - A compound of Formula (I): | 2017-06-01 |
20170152245 | BENZIMIDAZOLE COMPOUNDS AND THEIR APPLICATION IN CARDIOVASCULAR DISEASES - The present invention provides substituted benzimidazoles, pharmaceutical composition comprising the substituted benzimidazoles, and their use for preventing or treating a subject suffering from diseases or conditions associated with platelet activation aggregation and/or platelet activation. | 2017-06-01 |
20170152246 | Protein Kinase C Inhibitors and Uses Thereof - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2017-06-01 |
20170152247 | COMPOSITIONS AND METHODS FOR CONTROLLING NEMATODES - Compositions and methods for controlling nematodes are described herein, e.g., nematodes that infest plants or animals. The compounds include oxazoles, oxadiazoles and thiadiazoles. | 2017-06-01 |
20170152248 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS - The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders. | 2017-06-01 |
20170152249 | NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS - The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders. | 2017-06-01 |
20170152250 | INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES - The present invention relates to compounds of formula (I): | 2017-06-01 |
20170152251 | NOVEL CRYSTALLINE FORM OF 5-CHLORO-N-(METHYL)THIOPHENE-2-CARBOXAMIDE METHANESULFONATE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism. | 2017-06-01 |
20170152252 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion - The invention discloses compounds of formula I | 2017-06-01 |
20170152253 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV - A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising:
| 2017-06-01 |
20170152254 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer - A compound of Formula (I): | 2017-06-01 |
20170152255 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer - A compound of Formula (I): | 2017-06-01 |
20170152256 | 3,5-DICHLORO,4-(3,4-(CYCLO-)ALKOXYPHENYL)--2-CARBONYLOXY)ETHYL)PYRIDINE DERIVATIVES AS PDE-4 INHIBITORS - The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. | 2017-06-01 |
20170152257 | PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID HAVING A HYDROXYL GROUP ON THE PHENANTHRENE RING THEREOF, PREPARATION METHOD AND USE THEREOF - A phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof was synthesized, which exhibits potent activity as an anticancer agent against, such as breast cancer, lung cancer, and prostate cancer. | 2017-06-01 |
20170152258 | Substituted Pyridopyrazines as Syk Inhibitors - The present invention relates to pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R | 2017-06-01 |
20170152259 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR - Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is selected from a 3-9 membered carbon ring or a ring which is formed by 3-9 membered carbocyclic ring fused with benzo ring, and a 4-10 membered heterocyclic ring or a ring which is formed by 4-10 membered heterocyclic ring fused with benzo ring; Y and Z are independently selected from 4-9 membered saturated heterocyclic rings respectively; R | 2017-06-01 |
20170152260 | STAT3 INHIBITOR - Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer. | 2017-06-01 |
20170152261 | SMALL MOLECULES TARGETING REPEAT r(CGG) SEQUENCES - The invention provides a series of bioactive small molecules that target expanded r(CGG) repeats, termed r(CGG) | 2017-06-01 |
20170152262 | VINYLOGOUS THIOESTER COMPOUNDS AND METHODS OF USE - Provided herein are vinylogous thioester compounds and methods for using the compounds. | 2017-06-01 |
20170152263 | Substituted Indazole Compounds as IRAK4 Inhibitors - The present invention provides substituted indazole compound of formula (I) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK4 and/or for the treatment of diseases or disorders induced by IRAK4. | 2017-06-01 |
20170152264 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS - The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. | 2017-06-01 |
20170152265 | IMIDAZOTRIAZINONE COMPOUNDS - The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans. | 2017-06-01 |
20170152266 | Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS Based Prodrugs of Oxycodone and Uses thereof - The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxycodone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. | 2017-06-01 |
20170152267 | BENZOPYRYLIUM COMPOUNDS - Compounds used as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 2017-06-01 |
20170152268 | NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT - The present invention relates to a novel indene derivative, a preparation method for the same, and a pharmaceutical composition for preventing or treating retinal disease comprising the same as an active ingredient. The novel indene derivative of the present invention, the optical isomer of the same, or the pharmaceutically acceptable salts of the same have excellent inhibitory efficiency of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). Therefore, the composition containing the same as an active ingredient can be effectively used as a pharmaceutical composition for preventing or treating retinal disease exemplified by retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardts disease, Usher syndrome, choroideremia, rod-cone or cone-rod dystrophy, ciliopathy, mitochondrial disorders, progressive retinal atrophy, degenerative retinal diseases, age-related macular degeneration (AMD), wet AMD, dry AMD, geographical atrophy, inherited or acquired macular degeneration, retinal photoreceptor diseases, retinal pigment epithelial diseases, diabetic retinopathy, cystic macular edema, uveitis, retinal detachment, traumatic retinal injury, iatrogenic retinal injury, macular holes, macular capillarectasia, ganglion cell diseases, optic nerve diseases, glaucoma, optic neuropathy, ischemic retinal diseases, retinopathy of prematurity, occlusion of retinal vessels, inherited macroaneurysm, retinal vascular diseases, ophthalmic vascular diseases, glaucomatous retinal neurodegeneration, ischemic optic neuropathy and the like. | 2017-06-01 |
20170152269 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS CDK INHIBITORS - The present invention provides a fused bicyclic compound according to formula (H) or a pharmaceutically acceptable salt thereof, wherein L is —S— or —O—; M is —CH═, —N═ or —CJ=, wherein J is a non-hydrogen monovalent group; and W, G | 2017-06-01 |
20170152270 | METHOD FOR PRODUCING PYRIDINE COMPOUND - A pyridine compound represented by formula (1) that is useful as an insecticide is produced by reacting a compound represented by formula (2) and a compound represented by formula (3). In formula (2) L | 2017-06-01 |
20170152271 | GAK MODULATORS AS ANTIVIRALS - The present invention relates to the use of a class of novel isothiazolo[4,3-b]pyridine derivatives as well as to pharmaceutical compositions comprising one or more of said isothiazolo[4,3-b]pyridine derivatives and one or more pharmaceutically acceptable excipients as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as viral diseases. | 2017-06-01 |
20170152272 | LOW PH SYSNTHESIS OF ZINC-LYSINE COMPLEX - The disclosure provides an improved synthesis for a zinc-lysine complex having the formula [Zn(C | 2017-06-01 |
20170152273 | Topical Pharmaceutical Formulations For Treating Inflammatory-Related Conditions - Topical pharmaceutical formulations, and methods of treating inflammatory conditions with these formulations, are disclosed. | 2017-06-01 |
20170152274 | CHARGED LINKERS AND THEIR USES FOR CONJUGATION - Cell binding agent-drug conjugates comprising phosphinate-based charged linkers and methods of using such linkers and conjugates are provided. | 2017-06-01 |
20170152275 | 5'-DIBENZYL PHOSPHATES OF 5-AZACYTIDINE OR 2'-DEOXY-5-AZACYTIDINE - The present invention relates to a novel compound represented by formula (1), or salt thereof, | 2017-06-01 |
20170152276 | NOVEL SALT OF TENOFOVIR DISOPROXIL - Disclosed is a novel tenofovir disoproxil edisylate salt having the structure of Chemical Formula 1. | 2017-06-01 |
20170152277 | METHODS OF FORMING THIN FILM AND FABRICATING INTEGRATED CIRCUIT DEVICE USING NIOBIUM COMPOUND - Disclosed herein is a method of forming a thin film. The method includes forming a niobium-containing film by using a niobium precursor composition and a reactant, the niobium precursor composition including a niobium compound represented by Formula (1): | 2017-06-01 |
20170152278 | Depolymerisation Of Lignin In Biomass - A method of obtaining depolymerized lignin from biomass using a transition metal catalyst and a solvent mixture of organic solvent and water. The invention further relates to a composition obtainable by the method and the production of fuel. | 2017-06-01 |
20170152279 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 - The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit β-secretase. | 2017-06-01 |
20170152280 | SCAPHOPETALONE ANALOGS AND THEIR USES - The present disclosure relates to scaphopetalone analogs, methods of making the analogs, and their uses. | 2017-06-01 |
20170152281 | Crystalline solvate forms of a pharmaceutical - The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions. | 2017-06-01 |
20170152282 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME - The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 2017-06-01 |
20170152283 | INHIBITORS OF THE FARNESOID X RECEPTOR AND USES IN MEDICINE - Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R | 2017-06-01 |
20170152284 | NEUROACTIVE 19-ALKOXY-17(20)-Z-VINYLCYANO-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME - The present disclosure is generally directed to neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 2017-06-01 |
20170152285 | EXTRACTING METHOD OF KUGUACIN, PHARMACEUTICAL COMPOSITION COMPRISING THE KUGUACIN AND USE THEREOF - The present invention is related to an extracting method of kuguacin, pharmaceutical composition comprising the kuguacin and use thereof, specifically related to a use of the kuguacin for treating periodontal diseases. | 2017-06-01 |
20170152286 | STAPLED HELICAL PEPTIDES AND METHODS OF SYNTHESIS - The present disclosure relates to the design and generation of stapled helical peptides that perturb protein-protein interactions (PPIs). The methods disclosed herein for preparing stapled peptides involve providing a peptide having a first amino acid that is functionalized with a salicylaldehyde ester side group and a second amino acid functionalized with a 1,2-hydroxyl amine side group; reacting the first and second amino acids to generate an N,O-benzylidene acetal moiety; and performing acidolysis of the resultant N,O-benzylidene acetal moiety to generate the stapled peptide. In many forms, the stapled helical peptides described herein are not hydrophobic. | 2017-06-01 |
20170152287 | METHODS AND COMPOSITIONS FOR SITE-SPECIFIC LABELING OF PEPTIDES AND PROTEINS - Methods and compositions are provided for covalently linking a chemical species to a recombinant or synthetic polypeptide. The methods involve the reaction of a thioester-comprising polypeptide with a reagent comprising a reactive amino-thiol group connected to the chemical species which is to be covalently linked to the polypeptide, via a linker. Such chemical species can be a functional group, a label or tag molecule, a biological molecule, a ligand, or a solid support. Efficient and catalyst-free methods for C-terminal protein labeling are also provided. The methods expand current capabilities in the area of protein functionalization, providing useful and complementary tools for the isolation, detection, characterization, and analysis of proteins in a variety of in vitro and in vivo applications. | 2017-06-01 |
20170152288 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY - The present invention relates to the use for affinity purification of an antibody or a fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material. | 2017-06-01 |